Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA warning letters

This article was originally published in The Tan Sheet

Executive Summary

Sixteen dietary supplement and hormone cream marketers have received warning letters for "making unproven claims that tout the benefits of their 'alternative hormone therapy' products in treating or preventing serious diseases including cancer, heart disease and osteoporosis," FDA announces Nov. 10. Unproven claims include "reversing osteoporosis-related bone loss and increasing bone density"; "reducing, arresting or inhibiting the growth of cancer cells" and "treating various forms of arthritis." Bio-Health, Greatest Herbs on Earth and Suzanne's Natural Foods were among the firms warned. In a joint effort, FTC notified 34 websites promoting "alternative hormone therapy" that their products lack "competent and reliable scientific evidence" to support their claims...

You may also be interested in...

“Natural” Progesterone Still Being Marketed Despite Warning Letters – FTC

More than half of the 34 Web site operators who received warning letters from the Federal Trade Commission regarding misleading claims for "natural" progesterone creams continue to sell the products with claims they are safe and can cure certain diseases, the commission reported in testimony to a Senate committee April 19

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts